who's who

3 Houston innovators to know this week

This week's Houston innovators to know includes Tudor Palaghita of Camppedia, Robert Kester of Honeywell, and Ed Wooten of Smith. Photos courtesy

This week's Houston innovators to know are all using technology — but in completely different ways and across various sectors.

From creating a circular and sustainable economy for your company's technology to an online platform for your child's various activities — and even a socially distant way of checking temperatures — here is this week's who's who of Houston innovation.

Tudor Palaghita, CEO and founder of Camppedia

Tudor Palaghita has advanced his startup, Camppedia, so that parents can have virtual and in-person activities for their kids this summer. Photo courtesy of Camppedia

Like most of the world, Tudor Palaghita's year isn't going as planned. The founder of Camppedia — an online marketplace and tool for parents finding and managing their kids' activities — was hoping this summer was going to be his company's break-out moment and proof of concept. Instead, he's had to act quickly and pivot to focus on community and virtual opportunities.

"If anything, the pandemic forced us to move a lot of things forward," Palaghita says on the recent episode of the Houston Innovators Podcast. "The focus on the community was also something coming earlier than planned, but it was the most wonderful thing to come out of this. It really feels like everybody came together to give and to help each other."

Camppedia's business model is to give local camp and program providers — mostly small businesses, Palaghita says — a place to seamlessly reach parents. Now, these providers need Camppedia's platform more than ever as parents seek options a as they return to work or continue to look for at-home entertainment for their kids. Click here to read more.

Robert Kester, founder of Rebellion Photonics and president and general manager at Honeywell

Robert Kester found a new use for his temperature monitoring tech he created for the oil and gas industry. Photo courtesy of Honeywell

As the pandemic began to spread across the country, Robert Kester saw an opportunity for his technology he built for the oil and gas industry. Kester founded Rebellion Photonics, which Honeywell acquired in December of last year, and the company's ThermoRebellion temperature software uses infrared imaging technology and artificial intelligence to quickly conduct non-invasive screenings of people before they enter offices, banks, airports, as businesses begin to reopen.

"The key component is our software powered by artificial intelligence," Kester tells InnovationMap. "Our imaging systems leverage a decade of experience in the most advanced imaging technologies for gas leak detection, fire detection, and intrusion monitoring applications. The system features uncooled high-resolution FPA infrared sensors allowing for each pixel to be assessed for temperature."

By Kester's and his team's estimates, the ThermoRebllion system will be ready to deploy as early as June. Click here to read more.

Ed Wooten, director of IT asset disposition at Smith

Building a circular economy for electronics requires attention to detail in the areas of design, buyback, or return systems, advanced recycling and recapturing, durability and repair, and urban mining, writes Ed Wooten. Photo courtesy of Smith

For 20 years, Ed Wooten has worked to help clients figure out how to navigate the processes of buyback, recycling, and repair in order to create sustainable and profitable solutions to reduce e-waste.

"The world produces 40 million tons of e-waste annually, and only 20 percent of that is being disposed of properly," Wooten writes in a guest column for InnovationMap. "A circular economy is a system in which all materials and components are kept at their highest value and where e-waste is essentially designed out of the system."

Wooten gives his advice for creating a circular economy. Click here to read more.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News